Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dongkook Pharmaceutical Co Ltd
Net Income (Common)
Dongkook Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
|
Net Income (Common)
₩66B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩191.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
₩267B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩169.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
70%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
₩5.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Net Income (Common)
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Dongkook Pharmaceutical Co Ltd
Glance View
DongKook Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2007-05-29. The firm develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. The company also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The firm distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
See Also
What is Dongkook Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
66B
KRW
Based on the financial report for Dec 31, 2025, Dongkook Pharmaceutical Co Ltd's Net Income (Common) amounts to 66B KRW.
What is Dongkook Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
9%
Over the last year, the Net Income (Common) growth was 8%. The average annual Net Income (Common) growth rates for Dongkook Pharmaceutical Co Ltd have been 8% over the past three years , 3% over the past five years , and 9% over the past ten years .
